51. Transgenic Expression of Soluble Human CD5 Enhances Experimentally-Induced Autoimmune and Anti-Tumoral Immune Responses
- Author
-
José Alberola-Ila, Jordi Sintes, Mario Martínez-Florensa, Kevin S. Cashman, Ramón Merino, Gloria Soldevila, Manel Ramos-Casals, Chander Raman, Inês Simões, Pablo Engel, Rafael Fenutría, Vanesa G. Martínez, Francisco Lozano, Victor Gil, Jesús Merino, Rodrigo Naves, Jorge Postigo, Universitat de Barcelona, Universidad de Cantabria, Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, Red Española de Investigación en Patología Infecciosa, Instituto de Salud Carlos III, European Commission, Fibrostatin, National Institutes of Health (US), and National Multiple Sclerosis Society (US)
- Subjects
Melanomas ,Anatomy and Physiology ,Skin Neoplasms ,Melsa ,Cancer Treatment ,lcsh:Medicine ,ComputingMilieux_LEGALASPECTSOFCOMPUTING ,Autoimmunity ,Antígens ,Polymerase Chain Reaction ,Mice ,Resposta immunitària ,Immune Physiology ,IL-2 receptor ,Lymphocytes ,lcsh:Science ,Lymph node ,Immune Response ,Multidisciplinary ,biology ,FOXP3 ,hemic and immune systems ,Animal Models ,Natural killer T cell ,Flow Cytometry ,medicine.anatomical_structure ,Cèl·lules T ,Oncology ,Medicine ,Immunotherapy ,Antibody ,Research Article ,Encephalomyelitis, Autoimmune, Experimental ,Cèl·lules B ,Immunology ,T cells ,Spleen ,chemical and pharmacologic phenomena ,Malignant Skin Neoplasms ,Enzyme-Linked Immunosorbent Assay ,Mice, Transgenic ,Dermatology ,CD5 Antigens ,Limfòcits ,Immunomodulation ,Immune system ,Model Organisms ,medicine ,Animals ,Humans ,Immune response ,Antigens ,Biology ,DNA Primers ,Autoimmune disease ,B cells ,Base Sequence ,business.industry ,lcsh:R ,Immunity ,Neoplasms, Experimental ,medicine.disease ,Arthritis, Experimental ,Mice, Inbred C57BL ,Humoral Immunity ,biology.protein ,Mice, Inbred CBA ,lcsh:Q ,business - Abstract
This is an open-access article distributed under the terms of the Creative Commons Attribution License.-- et al., CD5 is a lymphoid-specific transmembrane glycoprotein constitutively expressed on thymocytes and mature T and B1a lymphocytes. Current data support the view that CD5 is a negative regulator of antigen-specific receptor-mediated signaling in these cells, and that this would likely be achieved through interaction with CD5 ligand/s (CD5L) of still undefined nature expressed on immune or accessory cells. To determine the functional consequence of loss of CD5/CD5L interaction in vivo, a new transgenic mouse line was generated (shCD5EμTg), expressing a circulating soluble form of human CD5 (shCD5) as a decoy to impair membrane-bound CD5 function. These shCD5EmTg mice showed an enhanced response to autologous antigens, as deduced from the presentation of more severe forms of experimentally inducible autoimmune disease (collagen-induced arthritis, CIA; and experimental autoimmune encephalitis, EAE), as well as an increased antitumoral response in non-orthotopic cancer models (B16 melanoma). This enhancement of the immune response was in agreement with the finding of significantly reduced proportions of spleen and lymph node Treg cells (CD4+CD25+FoxP3+), and of peritoneal IL-10-producing and CD5+ B cells, as well as an increased proportion of spleen NKT cells in shCD5EμTg mice. Similar changes in lymphocyte subpopulations were observed in wild-type mice following repeated administration of exogenous recombinant shCD5 protein. These data reveal the relevant role played by CD5/CD5L interactions on the homeostasis of some functionally relevant lymphocyte subpopulations and the modulation of immune responses to autologous antigens., This study was supported by grants from the Spanish Ministerio de Economía y Competitividad [Plan Nacional de I+D+i, SAF2010-19717], Generalitat de Catalunya [2009SGR1101], and Instituto de Salud Carlos III [Spanish Network for Research in Infectious Diseases, REIPI RD12/0015/0018] to FL, from Spanish Ministerio de Economía y Competitividad [SAF2011-22463], co-funded by the European Regional Development Fund, to RM, from Ministerio de Economía y Competitividad [SAF2012-34059], co-funded by the European Regional Development Fund, and the Spanish Ministerio de Economía y Competitividad (IPT2011-1527-010000) associated to Fibrostatin SL, to JM, and from NIH AI1076562 and National Multiple Sclerosis Society RG3891 to CR. MM-F and VGM are recipients of fellowships from Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya [2010TEM37] and from Spanish Ministerio de Economía y Competitividad [JCI-2010-06378], respectively.
- Published
- 2014